April 19, 2026 —
A newly published multicenter clinical study has added important momentum to the field of genetic hearing restoration. In the largest and longest follow-up trial reported so far for inherited hearing loss, investigators found that an adeno-associated virus (AAV)-based gene therapy restored hearing in most participants with OTOF-related deafness, with benefits lasting up to 2.5 years after treatment. The results were published in Nature and reported by researchers from Mass Eye and Ear, Mass General Brigham, and the Eye & ENT Hospital of Fudan University.
The trial enrolled 42 participants across eight sites in China, ranging in age from 0.8 to 32.3 years. All participants had autosomal recessive deafness 9 (DFNB9) caused by mutations in the OTOF gene, which encodes otoferlin, a protein required for inner ear hair cells to transmit sound signals to the brain. Without functional otoferlin, affected patients are born with severe-to-complete hearing loss. The study reported that about 90% of participants showed hearing improvement in the treated ear, with many beginning to respond within weeks and continuing to improve over time.
What makes this study especially notable is not only its size, but also the durability of the response. According to the published report, hearing recovery was gradual and stable over follow-up extending to 2.5 years, making this the longest reported follow-up for an OTOF gene therapy trial to date. The paper reported improvements in both objective and behavioral hearing measures, while the accompanying institutional release noted that many participants also improved in speech recognition and language development, especially younger children and those with healthier inner ear structures.
The therapeutic strategy relies on AAV as the delivery vehicle. In this study, researchers used AAV1-hOTOF, delivering a functional copy of the OTOF gene to inner ear cells through a single injection into the inner ear. Because the OTOF coding sequence is too large for standard single-AAV packaging, the treatment uses a split-gene strategy, enabling delivery of the therapeutic sequence in a form that can restore otoferlin expression in target cells. The success of this approach is another strong example of how AAV remains one of the most adaptable and clinically important vector systems in gene therapy, including for targets that present packaging challenges.
The hearing restoration data are especially encouraging because they extend beyond very young children. Prior OTOF studies had already shown promising outcomes in smaller pediatric cohorts, but this larger study included infants, children, and adults. While the strongest responses were generally seen in younger participants, the paper and institutional release both note that some adults also experienced meaningful hearing recovery, suggesting that the therapeutic window may be broader than previously assumed.
Just as important, the therapy appeared to be well tolerated, with no serious treatment-related adverse events reported in the study population. That safety profile, combined with the observed efficacy, strengthens the case for AAV-mediated gene replacement as a viable treatment path for certain forms of inherited deafness. At the same time, the authors noted that not all patients responded, and longer-term follow-up will still be needed to determine how durable the benefit remains over many years.
Taken together, these results represent an important advance for the hearing-loss field. OTOF-related deafness is rare, but it is also a strong proof-of-concept indication for genetic hearing restoration because it is caused by defects in a single gene with a well-defined biologic role. Success here supports broader efforts to develop gene therapies for other inherited hearing disorders and may also accelerate interest in newborn screening, early genetic diagnosis, and earlier intervention. The study’s authors have said they hope to bring this work into future U.S. trials and expand the platform to other genetic forms of hearing loss.
